strategic initiatives

ISPE Funded Manuscripts Initiative

ISPE annually funds proposals for manuscripts that could be used for guideline development, or reference documents for pharmacoepidemiology, including pharmacovigilance, drug utilization research, outcomes research, comparative effectiveness research, and therapeutic risk management. 

For a list of ISPE Endorsed Manuscripts click here


ISPE Funded Manuscript Process


Suggested topics of interest to the Society include:

  • Methodological topics/considerations in the area of COVID-19 vaccines and therapeutics safety ‎and effectiveness
  • Real-world evidence for regulatory decision-making
  • Real-world data quality and transparency, acceptable methods and approaches for data handling issues (e.g., missing data, bias control), use of next-generation registries
  • Precision medicine
  • Patient-generated health data
  • Signal detection in emerging large data sets such as EHR, social media, or device generated data (e.g., wearables, implanted devices), or device generated data (e.g., wearables, implanted devices)
  • Use of pharmacological / mechanistic data in pharmacoepidemiologic studies
  • AI and machine learning approaches to examine causal hypotheses
  • New methods in pharmacoepidemiology
  • Best practices related to specific approaches in pharmacoepidemiology
  • Formal evaluation of risk minimization approaches
  • Use of implementation science, including mixed methods, in design, implementation, and/or evaluation of risk minimization measures
  • Measuring impact of pharmacovigilance activities
  • Guidance/methods (design/analysis) of multi-database studies
  • Impact of critical global issues on pharmacoepidemiology (e.g., climate change, migration, refugees, gender equality, poverty, aging, sustainable development
  • Any topic contributing to ISPE's strategic mission


Proposal are assessed against the following criteria:

  • Appropriateness of issue to the general ISPE membership
  • General interest of topic to ISPE membership
  • Feasibility to accomplish the stated objectives
  • Importance (or significance) of proposal to the field of pharmacoepidemiology
  • Visibility (the extent to which the proposed manuscript will be used and, if so, raise the visibility of pharmacoepidemiology)
  • Collaboration among multiple organizations, work sectors, and geographic regions, and
  • Consistency with ISPE strategic goals, objectives and priorities


Proposals must conform to the format described in this document.

Submissions for 2023, which may only be submitted online here, are now being accepted with a deadline of 11:59 PM US Eastern Time on Sunday, October 1, 2023. The deadline will not be extended, and proposals submitted via other means will not be accepted.


General Timeline

Oct 1 – Submission deadline

Oct 31 – Joint Manuscript Proposal Review Subcommittee completes first review; if applicable, feedback is provided to writing teams and revised proposals requested

Nov 30 – If applicable, author responses to feedback due back to ISPE

Dec 20 – Joint Manuscript Proposal Review Subcommittee makes final selections; notifications to writing team lead contact